Cardiac resynchronization therapy is certainly cardiac therapy, but how much resynchronization and how much...

Area of Science:

• Cardiology
• Electrophysiology
• Medical Device Technology

Background:

• Cardiac resynchronization therapy (CRT) is standard for heart failure patients with specific criteria (QRS >120 ms, EF <35%, NYHA II-IV) refractory to medical therapy.
• Observed benefits in randomized trials are attributed to physiological changes like increased cardiac output or reduced myocardial oxygen consumption.
• The term CRT implies benefits arise from restoring synchrony between ventricles or within the left ventricle.

Purpose of the Study:

• To examine the relative contributions of ventricular resynchronization and atrioventricular (AV) delay shortening to the clinical efficacy of CRT.
• To question whether AV delay optimization, termed 'AV optimization,' is mislabeled as 'resynchronization' when it drives CRT benefits.

Main Methods:

• Review and examination of existing evidence on the mechanisms underlying CRT efficacy.
• Analysis of randomized trial data focusing on hard outcomes attributed to CRT.
• Comparative assessment of the impact of ventricular synchrony versus AV delay shortening.

Main Results:

• Evidence suggests that benefits from CRT may significantly arise from favorable shortening of the AV delay ('AV optimization').
• The contribution of true ventricular resynchronization to clinical outcomes requires further elucidation.
• The current definition of CRT may be too broad if AV optimization is a primary driver of benefit.

Conclusions:

• The clinical efficacy of CRT is undoubted, but the precise mechanisms require clarification.
• A substantial portion of CRT's benefits might be attributable to AV delay optimization rather than solely ventricular resynchronization.
• Re-evaluation of the term 'Cardiac Resynchronization Therapy' may be necessary to accurately reflect its therapeutic mechanisms.